公开(公告)号：WO2013008250A3

公开(公告)日：2013-03-07

申请号：PCT/IN2012000468

申请日：2012-07-02

Applicant: REDDYS LAB LTD DR ,  PEDDY VISHWESHWAR ,  BOGE RAJESHAM ,  CHIMALA VENKATA RAMANA REDDY ,  MUDAPAKA VAMSI KRISHNA ,  PATHIVADA DEEPIKA ,  NALIVELA VENU ,  KUMAR RAMYA ,  RAMAKRISHNAN SRIVIDYA ,  RANGINENI SRINIVASULU ,  SAMINENI LAXMI CHARAN

Inventor： PEDDY VISHWESHWAR ,  BOGE RAJESHAM ,  CHIMALA VENKATA RAMANA REDDY ,  MUDAPAKA VAMSI KRISHNA ,  PATHIVADA DEEPIKA ,  NALIVELA VENU ,  KUMAR RAMYA ,  RAMAKRISHNAN SRIVIDYA ,  RANGINENI SRINIVASULU ,  SAMINENI LAXMI CHARAN

IPC: C07C271/28 ,  A61K31/27 ,  C07C269/08

CPC classification number: C07C271/28 ,  A61K31/325

Abstract: A crystalline form of retigabine, process for its preparation and processes for preparation of mixture of known retigabine modifications and pharmaceutical composition are provided.

Abstract translation: 提供结晶形式的瑞替加滨，其制备方法和制备已知的瑞替加滨改性物和药物组合物的混合物的方法。

公开(公告)号：WO2013008250A2

公开(公告)日：2013-01-17

申请号：PCT/IN2012/000468

申请日：2012-07-02

Applicant: DR.REDDYS LABORATORIES LIMITED. ,  PEDDY, Vishweshwar ,  BOGE, Rajesham ,  CHIMALA, Venkata Ramana Reddy ,  MUDAPAKA, Vamsi Krishna ,  PATHIVADA, Deepika ,  NALIVELA, Venu ,  KUMAR, Ramya ,  RAMAKRISHNAN, Srividya ,  RANGINENI, Srinivasulu ,  SAMINENI, Laxmi Charan

Inventor： PEDDY, Vishweshwar ,  BOGE, Rajesham ,  CHIMALA, Venkata Ramana Reddy ,  MUDAPAKA, Vamsi Krishna ,  PATHIVADA, Deepika ,  NALIVELA, Venu ,  KUMAR, Ramya ,  RAMAKRISHNAN, Srividya ,  RANGINENI, Srinivasulu ,  SAMINENI, Laxmi Charan

CPC classification number: C07C271/28 ,  A61K31/325

Abstract: Aspects of the present invention relate to crystalline form of retigabine, process for its preparation and processes for preparation of mixture of known retigabine modifications and pharmaceutical composition comprising thereof.

Abstract translation: 本发明的方面涉及瑞替加林的结晶形式，其制备方法以及制备已知的瑞替加滨改性物的混合物的方法以及包含其的药物组合物。

公开(公告)号：WO2012037187A2

公开(公告)日：2012-03-22

申请号：PCT/US2011/051501

申请日：2011-09-14

Applicant: DR. REDDY'S LABORATORIES LTD. ,  DR. REDDY'S LABORATORIES, INC. ,  KANNIAH, Sundra, Lakshmi ,  BOGE, Rajesham ,  SUBBAREDDY, Peddireddy ,  KANWAR, Lalita ,  RAMAKRISHNAN, Srividya ,  KUMAR, Ramya ,  BANDICHHOR, Rakeshwar ,  LEKKALA, Amarnath Reddy ,  MYLAVARAPU, Ravi Kumar ,  RAGHUNATH, Vagwala

Inventor： KANNIAH, Sundra, Lakshmi ,  BOGE, Rajesham ,  SUBBAREDDY, Peddireddy ,  KANWAR, Lalita ,  RAMAKRISHNAN, Srividya ,  KUMAR, Ramya ,  BANDICHHOR, Rakeshwar ,  LEKKALA, Amarnath Reddy ,  MYLAVARAPU, Ravi Kumar ,  RAGHUNATH, Vagwala

IPC: C07D403/12 ,  C07D403/10 ,  C07C53/10 ,  C07C53/08 ,  A61K31/55 ,  A61K31/404

CPC classification number: C07D403/12 ,  C07D209/12

Abstract: Aspects of the present disclosure include crystalline bazedoxifene free base, crystalline bazedoxifene acetate Form D, and processes for their preparation. The drug compound having the adopted name "bazedoxifene acetate" has a chemical name 1-[4-(2-azepan-1-yl-ethoxy)benzyl]-2-(4-hydroxyphenyl)-3-methyl-1 H -indol-5-ol acetic acid, and has the chemical structure shown below as Formula I.

Abstract translation: 本公开内容的方面包括结晶巴西多昔芬游离碱，结晶乙酸巴多昔芬乙酸酯形式D及其制备方法。 具有采用的名称为“醋酸巴多昔芬”的药物化合物具有化学名称1- [4-（2-氮杂环庚烷-1-基 - 乙氧基）苄基] -2-（4-羟基苯基）-3-甲基-1H-吲哚-2-基） 5-醇乙酸，具有如下式I所示的化学结构。

公开(公告)号：WO2012037187A3

公开(公告)日：2012-06-07

申请号：PCT/US2011051501

申请日：2011-09-14

Applicant: REDDYS LAB LTD DR ,  REDDYS LAB INC DR ,  KANNIAH SUNDRA LAKSHMI ,  BOGE RAJESHAM ,  SUBBAREDDY PEDDIREDDY ,  KANWAR LALITA ,  RAMAKRISHNAN SRIVIDYA ,  KUMAR RAMYA ,  BANDICHHOR RAKESHWAR ,  LEKKALA AMARNATH REDDY ,  MYLAVARAPU RAVI KUMAR ,  RAGHUNATH VAGWALA

Inventor： KANNIAH SUNDRA LAKSHMI ,  BOGE RAJESHAM ,  SUBBAREDDY PEDDIREDDY ,  KANWAR LALITA ,  RAMAKRISHNAN SRIVIDYA ,  KUMAR RAMYA ,  BANDICHHOR RAKESHWAR ,  LEKKALA AMARNATH REDDY ,  MYLAVARAPU RAVI KUMAR ,  RAGHUNATH VAGWALA

IPC: C07D403/12 ,  A61K31/404 ,  A61K31/55 ,  C07C53/08 ,  C07C53/10 ,  C07D403/10

CPC classification number: C07D403/12 ,  C07D209/12

Abstract: Aspects of the present disclosure include crystalline bazedoxifene free base, crystalline bazedoxifene acetate Form D, and processes for their preparation. The drug compound having the adopted name "bazedoxifene acetate" has a chemical name 1-[4-(2-azepan-1-yl-ethoxy)benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol acetic acid, and has the chemical structure shown below as Formula I.

Abstract translation: 本公开的方面包括结晶巴西多昔芬游离碱，结晶苯卓昔芬乙酸盐晶型D及其制备方法。 采用名称“醋酸巴泽多昔芬”的药物化合物具有化学名称1- [4-（2-氮杂环庚烷-1-基 - 乙氧基）苄基] -2-（4-羟基苯基）-3-甲基-1H-吲哚-1-基] 5-醇乙酸，并具有如下式I所示的化学结构。